Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase”

100 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 100 results

Testing effectiveness (Phase 2)UnknownNCT04485260
What this trial is testing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
Myelofibrosis
Kartos Therapeutics, Inc. 36
Large-scale testing (Phase 3)Active Not RecruitingNCT04603495
What this trial is testing

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Novartis Pharmaceuticals 430
Testing effectiveness (Phase 2)Active Not RecruitingNCT03645824
What this trial is testing

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

Who this might be right for
Myelofibrosis
Stichting Hemato-Oncologie voor Volwassenen Nederland 61
Large-scale testing (Phase 3)Ended earlyNCT04551053
What this trial is testing

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 177
Testing effectiveness (Phase 2)Ended earlyNCT03627403
What this trial is testing

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
University of Utah 17
Testing effectiveness (Phase 2)Study completedNCT00397813
What this trial is testing

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Who this might be right for
Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndrome+11 more
Fred Hutchinson Cancer Center 77
Early research (Phase 1)Ended earlyNCT01291784
What this trial is testing

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more
John Mascarenhas 3
Testing effectiveness (Phase 2)Study completedNCT01787487
What this trial is testing

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Who this might be right for
Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMyelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more
M.D. Anderson Cancer Center 121
Testing effectiveness (Phase 2)UnknownNCT04640532
What this trial is testing

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+1 more
Kartos Therapeutics, Inc. 116
Large-scale testing (Phase 3)Active Not RecruitingNCT04717414
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Who this might be right for
Myeloproliferative DisordersMyelofibrosisPrimary Myelofibrosis+2 more
Celgene 313
Testing effectiveness (Phase 2)Study completedNCT01200498
What this trial is testing

Study of SB939 in Subjects With Myelofibrosis

Who this might be right for
Myeloproliferative Disorders
M.D. Anderson Cancer Center 23
Large-scale testing (Phase 3)Active Not RecruitingNCT03165734
What this trial is testing

Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum 407
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Large-scale testing (Phase 3)Study completedNCT04173494
What this trial is testing

Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 195
Testing effectiveness (Phase 2)Active Not RecruitingNCT04455841
What this trial is testing

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Who this might be right for
AnemiaPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
Incyte Corporation 84
Testing effectiveness (Phase 2)Study completedNCT01644110
What this trial is testing

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

Who this might be right for
Primary MyelofibrosisSecondary MyelofibrosisPMF+3 more
University of Ulm 96
Testing effectiveness (Phase 2)Study completedNCT01692366
What this trial is testing

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Who this might be right for
Myelofibrosis
Bristol-Myers Squibb 8
Not applicableLooking for participantsNCT05882773
What this trial is testing

Asian Myeloproliferative Neoplasm (MPN) Registry

Who this might be right for
Myeloproliferative NeoplasmPolycythemia VeraEssential Thrombocythemia+5 more
The University of Hong Kong 1,000
Testing effectiveness (Phase 2)WithdrawnNCT04054245
What this trial is testing

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Myelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
M.D. Anderson Cancer Center
Not applicableUnknownNCT05883904
What this trial is testing

Real World Evidence of Fedratinib Effectiveness in MF

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Gruppo Italiano Malattie EMatologiche dell'Adulto 93
Next Page